ARL17 Inhibitors
ARL17 inhibitors of the PI3K/Akt pathway, such as Wortmannin and LY294002, can alter cellular growth and survival signals, thus potentially adjusting the regulatory context for ARL17. Similarly, mTOR inhibitors like Rapamycin have broad effects on cell growth and metabolism, which can have downstream effects on proteins like ARL17. Inhibitors targeting the MAPK pathway, such as PD98059, SP600125, SB203580, and U0126, can impact cellular responses to various stimuli, including stress, growth factors, and cytokines, thus creating an indirect effect on ARL17's activity.
Gefitinib and Dasatinib, which target growth factor receptors and tyrosine kinases respectively, can change the signaling landscape of a cell by inhibiting pathways that may be upstream or parallel to those involving ARL17. Y-27632, as a ROCK inhibitor, affects the cytoskeleton and related signaling, potentially influencing ARL17's function in cellular structure and motility. Additionally, Go6983, by inhibiting protein kinase C, can affect numerous signaling pathways, possibly altering the functional state of ARL17. These compounds represent a chemical toolkit that can indirectly influence the function of ARL17 by modulating the activity of related signaling pathways or cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent PI3K inhibitor that can disrupt downstream signaling pathways involving ARL17 by inhibiting PI3K-dependent processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A synthetic molecule that inhibits PI3K, potentially altering signaling cascades and indirectly affecting ARL17 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can alter the activation state of downstream effectors that may interact with ARL17. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Specifically inhibits the Akt signaling pathway, which may intersect with ARL17's regulatory network. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, which could disrupt the MAPK/ERK pathway and indirectly modulate ARL17's role within that pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, potentially affecting ARL17's function by altering stress response signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
P38 MAPK inhibitor that could impact ARL17's function by influencing inflammatory signaling pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR inhibitor that can disrupt growth factor signaling pathways potentially connected to ARL17's function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A broad-spectrum tyrosine kinase inhibitor that can affect multiple signaling pathways involving ARL17. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that can alter cytoskeletal dynamics and potentially influence ARL17's role in cellular processes. | ||||||